A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with ...

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with international partners, has designed a strategy for preventing the cardiotoxic ...

Cardiotoxicity, however, is an important adverse effect that is observed with the use of this agent. Particularly with concurrent anthracycline treatment, the incidence of cardiotoxicity increases ...

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with ...

CHICAGO -- Sacubitril/valsartan (Entresto) was effective at keeping cardiotoxicity at bay in high-risk people receiving anthracycline chemotherapy in the SARAH trial. Cancer patients were less ...

The authors showed that the cardiotoxicity is probably due to inhibition of one specific target of imatinib, the c-Abl protein kinase. Cardiomyocyte death was largely prevented by deactivation of ...

A second study used genetic variants, in addition to clinical and genetic factors, to identify those at highest risk for anthracycline-related cardiotoxicity. They evaluated 2,977 SNPs in 220 key drug ...

We read with interest the article by Marie Lund and colleagues published in The Lancet Oncology investigating the association ...

Heart failure resulting from treatments for non-cardiac medical conditions presents a significant challenge in clinical ...

The clinical utility of the cancer chemotherapeutic agent doxorubicin (DOX) is limited by its cardiotoxicity. Doxorubicinol (DOXol), the major biometabolite of DOX, preferentially accumulates in ...

Dr Rebecca Dobson discussed the acute need to assess cardiovascular risk in cancer care, cardiotoxicity and the MDT in cardio ...

CardioOncology, shows that administration of the SGLT2 inhibitor empagliflozin to pigs receiving anthracyclines preserves ...